Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

788.19 -1.13 (-0.14%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
3 Powerful Stocks Worthy of Magnificent 7 Status
These Potential Magnificent 7 stocks have quite a run ahead and could challenge the original seven in the second half. 
Via InvestorPlace
MarketBeat Week in Review – 7/8 - 7/12
Stocks took investors on quite a ride this week, with the S&P 500 hitting a new record high, then falling back on Thursday before rallying to end the week 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
The news likely didn't come as a big surprise to investors. 
Via The Motley Fool
Exposures Product Safety
Did Eli Lilly Just Get a Leg Up on Novo Nordisk?
Eli Lilly's latest milestone sets it apart from its rival Novo Nordisk. 
Via The Motley Fool
SPDR ETF Report For Friday, July 12
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, July 12. 
Via Talk Markets
Topics ETFs
In-Depth Analysis: Eli Lilly and Co Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Eli Lilly Announces CFO Change
Shares of Eli Lilly And Company (NYSE: LLY) are moving higher on Wednesday. Here's what you need to know. 
Via Benzinga
The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now
These potential trillion dollar stocks are the next companies poised to join the elite club and drive future market growth. 
Via InvestorPlace
The Weight Loss Market Can Surge To $400B By 2032, And These Stocks Will Rule It
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position. 
Via Talk Markets
With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with dose optimization studies planned for late 2024. The study will evaluate... 
Via Benzinga
Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study
A yearlong study at the University of Oxford suggests GLP-1 drugs could play a role in protecting brain health. 
Via Investor's Business Daily
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory risks. New warnings to be included in product information to ensure... 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
Should You Buy Eli Lilly Stock After Another Major Win?
It was a buy even before this development. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Novo Nordisk's 'Miracle' Weight Loss Drug Ozempic Linked To 48% Lower Risk Of Dementia, Study Finds
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other cognitive issues. 
Via Benzinga
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga
First Choice Neurology Pioneering Neurologists Administer the New FDA-Approved Drug Kisunla
JUPITER, Fla. - July 11, 2024 - PRLog -- First Choice Neurology, the largest neurology group in the United States, is set to make medical history next week as Dr. Jennifer Buczyner and Dr. Jeff Gelblum... 
Via PRLog
Exposures Product Safety
3 Future Blue-Chip Stocks That Could Make You Rich
Blue-chip stocks are the cream of the crop of the stock exchange market. Find out about the best future blue-chip stocks to invest in. 
Via InvestorPlace
Better Growth Play: Eli Lilly vs. Vanguard Growth Index Fund ETF Shares
Both equities have been incredible growth plays of late. 
Via The Motley Fool
Topics ETFs
Warren Buffett Recommends This Magnificent Index Fund. It Could Turn $500 Per Month Into $986,900
The S&P 500 is a group of businesses that are bound to perform well over time, according to Warren Buffett. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Jim Cramer has identified eight companies that could potentially reach a market cap of $1 trillion, including Elon Musk's Tesla, and Eli Lilly. 
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Investors might want to consider the top pharma stocks in the current environment as they are beating most others. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
A study shows that only one in four U.S. patients prescribed Novo Nordisk's weight-loss drugs Wegovy or Ozempic remain on the medication after two years, raising concerns about long-term adherence. 
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... 
Via Benzinga
Eli Lilly Finalizes Acquisition Agreement to Acquire Morphic for $3.2 Billion – InsideArbitrage
Via AB Newswire
Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors
Give some consideration to these names, each of which has a strong competitive advantage and catalysts driving their share price higher. 
Via InvestorPlace
3 Moonshot Stocks With the Potential to Turn $10K Into $1 Million
Want to turn your $10K into $1 million? Here are three high-growth potential stocks that can make it happen for you. 
Via InvestorPlace
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.